The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.

ABSTRACT:

Background

Prostate cancer (PCa) is characterised by great heterogeneity of the disease progression rate. Tumours range from insignificant and not life threatening to high risk for relapse ones. Consequently, a large number of patients undergo unnecessary treatment. miR-145 is a well-documented tumour suppressor and its expression, which is regulated by the p53 pathway, has been found to be decreased in the majority of human malignancies. The aim of our study was to evaluate the clinical utility of miR-145 for the prognostication of PCa.

Methods

Total RNA was isolated from 137 prostate tissue specimens obtained from 73 radical prostatectomy-treated PCa patients and 64 transurethral- or open prostatectomy-treated benign prostate hyperplasia (BPH) patients. Following polyadeny

SUBMITTER: Avgeris M 

PROVIDER: S-EPMC3694240 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature